Baseline characteristics and treatment regimens of the study cohorts
Variable . | Epo-G study I . | Epo-G study II . | Epo-G study III . | Epo-G study I-III . | IPSS/IMRAW* . |
|---|---|---|---|---|---|
| No. patients evaluable for response† | 21 | 50 | 52 | 123 | NA |
| No. patients evaluable for survival‡ | 22 | 53 | 54 | 129 | 334 |
| Median age, y (range) | 69 (43-87) | 70 (48-87) | 74 (47-87) | 72 (43-87) | 70 (16-96) |
| Sex | |||||
| Male | 16 | 27 | 29 | 72 | 188 |
| Female | 6 | 26 | 25 | 57 | 146 |
| FAB | |||||
| RA | 4 | 11 | 15 | 30 | 137 |
| RARS | 6 | 13 | 22 | 41 | 73 |
| RAEB | 12 | 29 | 17 | 58 | 124 |
| IPSS§ | |||||
| Low | 6 | 11 | 17 | 34 | 78 |
| Int-1 | 9 | 21 | 27 | 57 | 169 |
| Int-2 | 4 | 14 | 5 | 23 | 66 |
| High | 0 | 1 | 3 | 4 | 21 |
| Transfusion need | |||||
| Yes | 16 | 38 | 37 | 91 | Not known |
| No | 6 | 15 | 17 | 38 | Not known |
| Predictive group for response | |||||
| Good | 9 | 17 | 17 | 43 | Not known |
| Intermediate | 6 | 20 | 19 | 45 | Not known |
| Poor | 5 | 11 | 0 | 16 | Not known |
Variable . | Epo-G study I . | Epo-G study II . | Epo-G study III . | Epo-G study I-III . | IPSS/IMRAW* . |
|---|---|---|---|---|---|
| No. patients evaluable for response† | 21 | 50 | 52 | 123 | NA |
| No. patients evaluable for survival‡ | 22 | 53 | 54 | 129 | 334 |
| Median age, y (range) | 69 (43-87) | 70 (48-87) | 74 (47-87) | 72 (43-87) | 70 (16-96) |
| Sex | |||||
| Male | 16 | 27 | 29 | 72 | 188 |
| Female | 6 | 26 | 25 | 57 | 146 |
| FAB | |||||
| RA | 4 | 11 | 15 | 30 | 137 |
| RARS | 6 | 13 | 22 | 41 | 73 |
| RAEB | 12 | 29 | 17 | 58 | 124 |
| IPSS§ | |||||
| Low | 6 | 11 | 17 | 34 | 78 |
| Int-1 | 9 | 21 | 27 | 57 | 169 |
| Int-2 | 4 | 14 | 5 | 23 | 66 |
| High | 0 | 1 | 3 | 4 | 21 |
| Transfusion need | |||||
| Yes | 16 | 38 | 37 | 91 | Not known |
| No | 6 | 15 | 17 | 38 | Not known |
| Predictive group for response | |||||
| Good | 9 | 17 | 17 | 43 | Not known |
| Intermediate | 6 | 20 | 19 | 45 | Not known |
| Poor | 5 | 11 | 0 | 16 | Not known |
NA indicates not applicable.
The IPSS/IMRAW is an untreated cohort that originates from a merger of patients from 7 different studies. Baseline data on transfusion need and S-Epo level are unknown for these patients; hence it is not possible to group them according to the predictive model for response.
Evaluability for response: evaluable for survival and completed 6 weeks of treatment.
Evaluability for survival: (1) fulfilled study criteria, (2) started treatment, (3) possible to follow up.
Eleven patients did not have a successful cytogenetic analysis and could not be scored.